Lixisenatide

In plain language

Lixisenatide is a once-daily injection for type 2 diabetes in the GLP-1 drug family. It is based on a hormone found in Gila monster saliva and is now sold only inside a combination pen with basal insulin (Soliqua).

It works mainly at mealtime: it slows stomach emptying and prompts the pancreas to release insulin only when blood sugar is high, so it rarely causes low blood sugar by itself. Its main side effects are nausea and vomiting when starting.

For students

Lixisenatide is a 44-residue analogue of exendin-4(1-39) with six C-terminal lysines (about 4,858 Da), developed by Sanofi. It is a short-acting GLP-1 receptor agonist: pronounced gastric emptying effects but a limited 13-hour half-life, dosed once daily before the first meal.

The stand-alone product (Adlyxin in the U.S., Lyxumia in Europe) was discontinued in the U.S. in early 2023 for business reasons; the molecule remains available in Soliqua (insulin glargine plus lixisenatide). Its cardiovascular safety trial, ELIXA, was the first completed for any GLP-1 agonist and showed neither benefit nor harm in patients after acute coronary syndrome.

For researchers and instructors

Biochemistry. Derived from exendin-4 rather than human GLP-1, giving DPP-4 resistance through its sequence and C-terminal lysine extension that also promotes solubility.

Pharmacology. Short half-life and strong effect on gastric emptying produce a distinctly prandial profile; once-daily 20 mcg dosing with the first meal; use with basal insulin covers both fasting and postprandial glucose.

Human evidence. The GetGoal program (multiple Phase 3 trials) established HbA1c lowering and weight neutrality; ELIXA (6,068 patients with recent ACS) established cardiovascular safety.

Teaching point. ELIXA's neutral result set up the later cardiovascular benefit era led by liraglutide and semaglutide, a pivotal contrast in GLP-1 pharmacology history.